Your browser doesn't support javascript.
loading
Meta-analysis and systematic review of gout prevalence in the heart/lung transplantation population.
Chui, Benedict; Day, Richard; Umashankar, Eshwar; Abdel Shaheed, Christina; Keogh, Anne; Girgis, Laila; Penglase, Ross.
Afiliação
  • Chui B; Faculty of Medicine and Health, St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
  • Day R; Faculty of Medicine and Health, St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
  • Umashankar E; Department of Clinical Pharmacology, St Vincent's Hospital, Sydney, NSW, Australia.
  • Abdel Shaheed C; Faculty of Medicine and Health, St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
  • Keogh A; Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • Girgis L; Institute for Musculoskeletal Health, University of Sydney and Sydney Local Health District, Sydney, NSW, Australia.
  • Penglase R; Faculty of Medicine and Health, St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
Front Transplant ; 3: 1356058, 2024.
Article em En | MEDLINE | ID: mdl-38993785
ABSTRACT

Introduction:

Gout may complicate solid organ transplantation with potentially serious consequences. An accurate prevalence of gout in this population is unknown.

Objectives:

This study aimed to estimate the prevalence of gout in the heart and/or lung transplantation population through a systematic review and meta-analysis.

Methods:

MEDLINE, Embase, PsycINFO, CENTRAL and Cochrane Library (inception to February 2022) were searched for studies that reported the prevalence and/or incidence of gout in heart and/or lung transplant recipients. Two authors extracted outcomes data. Data were pooled using a random effects model. Overall quality of evidence was assessed using GRADE. Primary outcomes were the prevalence of pre- or post-transplant gout expressed as a prevalence rate (95% CI). Secondary outcomes included risk factors for gout, adverse events, and therapeutic complications of gout treatment.

Results:

Ten studies were included. Gout prevalence (PR) was 8% pre-transplant (PR = 0.08; 95% CI 0.05-0.12; 4 studies n = 651) and 6% post-transplant (PR = 0.06; 95% CI 0.06-0.06; 10 studies n = 45,298). Post-transplant gout prevalence in heart transplant recipients was almost three times higher than lung transplant recipients (PR = 0.16; 95% CI 0.13-0.20 vs. PR = 0.06; 95% CI 0.05-0.06 respectively). Patients with a pre-transplant history of gout had a higher risk of developing post-transplant gout than patients without (RR = 3.61; 95% CI 2.19-5.95). Factors associated with gout and outcomes for heart and/or lung transplant recipients with gout were comprehensively reviewed from the included studies.

Conclusion:

Gout is highly prevalent in heart and/or lung transplant patients. Pre-transplant gout is predictive of developing symptomatic post-transplant gout. This has significant implications for management of heart/lung transplant patients. Systematic Review Registration https//www.crd.york.ac.uk/, PROSPERO (CRD42020190632).
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article